



Portfolio – Preferred Drug List (PDL)

July 1, 2025

What is the MedImpact Preferred Drug List (PDL)?

The PDL is a list of commonly prescribed medications within select classes of drugs covered by your prescription drug plan. The PDL was created to promote clinically appropriate utilization of medications in a cost-effective manner.

Are the medications listed on the PDL the only drugs my physician can prescribe for me?

No. The PDL is a select list of commonly prescribed drugs and does not represent all preferred formulary medications available under your plan. The PDL does not limit your prescription coverage but is provided to encourage the use of preferred generic and brand name drugs within major therapeutic drug classes (e.g., Cardiovascular, Diabetes, etc.). For complete formulary information, visit your Plan website or refer to the phone number listed on your benefit card.

How do I get the greatest benefit from my PDL?

- **Print out the Preferred Drug List and take it with you when visiting your physician.**
- Ask your physician to prescribe generic medications whenever possible.
- When there is more than one brand name drug available for your medical condition, ask your physician to prescribe a preferred drug listed on your PDL. This should also reduce your copays.

Please note: The MedImpact PDL is subject to change due to updates and availability of generic alternatives. The PDL is not a complete list of formulary drugs; therefore, you should refer to your plan for a complete drug list and details of any additional coverage or quantity limit restrictions that may apply to certain medications.

PDL DRUG CATEGORY	GENERIC	PREFERRED BRAND	NON-PREFERRED BRAND
ALLERGY			
NASAL CORTICOSTEROIDS	azelastine/fluticasone OTC budesonide flunisolide fluticasone mometasone OTC triamcinolone	Qnasl Xhance	Beconase AQ Dymista Omnaris Ticanase Zetonna
OPHTHALMIC ANTIHISTAMINES	azelastine epinastine olopatadine	Alomide	Bepreve Emadine Lastacaft Pazeo
BEHAVIORAL HEALTH			
ADHD AGENTS	amphetamine sulfate dexamethylphenidate dextroamphetamine/ amphetamine dextroamphetamine/ amphetamine ER dextroamphetamine ER dextroamphetamine methylphenidate methylphenidate ER lisdexamfetamine dimesylate	Azstarys Jornay PM	Adhansia XR Adzenys ER Adzenys XR-ODT Aptensio XR Cotempla XR-ODT Daytrana Dyanavel XR Evekeo ODT Relexxii Qelbree Quillichew Quillivant Xelstrym Zenzedi
ANTIPSYCHOTICS	aripiprazole/ODT/oral solution	Abilify Asimtufii	Abilify Mycite

MedImpact.com

Copyright © 2025 MedImpact Healthcare Systems, Inc. All rights reserved. These materials are intended strictly for referential use by MedImpact's business partners. Any other use, or use by any other party, is strictly forbidden and requires written consent of MedImpact Healthcare Systems, Inc.





Portfolio – Preferred Drug List (PDL)

July 1, 2025

PDL DRUG CATEGORY	GENERIC	PREFERRED BRAND	NON-PREFERRED BRAND
	asenapine clozapine/ODT lurasidone olanzapine paliperidone quetiapine IR/XR risperidone risperidone ER ziprasidone	Abilify MaintennaAristada Invega Hafyera/ Sustenna/Trinza Perseris Rexulti Rykindo Uzedy Vraylar	Caplyta Fanapt Fazaclo Lybalvi quetiapine (150mg) Secuado Versacloz Zyprexa Relprevv
CARDIOVASCULAR			
LIPID-LOWERING AGENTS	atorvastatin ezetimibe fluvastatin IR/ER lovastatin IR/ER Livalo pravastatin rosuvastatin simvastatin tablet simvastatin/ezetimibe		Altoprev Atorvaliq Ezallor Sprinkle Flolipid Roszet Zypitamag
ANTICOAGULANTS	dabigatran rivaroxaban 2.5mg	Eliquis Xarelto	Bevyxxa Pradaxa Savaysa
PCSK9 INHIBITORS		Repatha	Praluent
ACL INHIBITORS		Nexletol Nexlizet	
DERMATOLOGY			
ACTINIC KERATOSIS AGENTS	diclofenac 3% fluorouracil 0.5% fluorouracil 5%	Tolak Klisyri	Carac 0.5% Fluoroplex Picato Zyclara
DIABETES			
DPP-4 INHIBITORS		Januvia Janumet Janumet XR	Jentadueto Jentadueto XR Kazano Kombiglyze XR Nesina (brand and authorized generic) Onglyza Oseni Tradjenta Zituvio (brand and authorized generic)
SGLT-2 INHIBITORS		Farxiga Jardiance Synjardy Synjardy XR Xigduo XR	Brenzavvy Inpefa Invokana Invokamet Invokamet XR Segluromet Steglatro
DPP-4 INHIBITOR AND SGLT-2 INHIBITOR COMBINATIONS		Glyxambi Trijardy XR	Qtern Steglujan
GLP-1 AGONISTS	exenatide	Mounjaro Ozempic	Adlyxin Bydureon



Portfolio – Preferred Drug List (PDL)

July 1, 2025

PDL DRUG CATEGORY	GENERIC	PREFERRED BRAND	NON-PREFERRED BRAND
		Rybelsus Trulicity	Bydureon BCise Byetta Liraglutide
INSULINS, RAPID-ACTING	insulin lispro	Humalog (U-200) Lyumjev	Admelog Afrezza Apidra Fiasp Novolog
INSULINS, SHORT-ACTING		Humulin	Novolin
INSULINS, LONG-ACTING		Semglee (yfgn) Tresiba Toujeo	Basaglar Levemir
INSULIN (LONG-ACTING) AND GLP-1 AGONIST COMBINATIONS		Soliqua Xultophy	
DIABETIC SUPPLIES		Abbott & Lifescan diabetic supplies (Precision, FreeStyle, FreeStyle Neo, Onetouch Ultra, Onetouch Verio) BD insulin syringes BD pen needles	All non-Abbott & non-Lifescan manufacturers of diabetic test strips and meters
ENDOCRINE			
ANDROGENS	me-testosterone testosterone cypionate testosterone enanthate testosterone gel testosterone 1% solution		Androderm patch Jatenzo Kyzatrex Methitest Natesto Striant Tlando Xyosted
ESTROGENS/ESTROGEN MODIFIERS	estradiol gel estradiol patch estradiol/norethindrone estropipate medroxyprogesterone norethindrone ac-eth progesterone, micronized	Bijuva Combipatch Crinone Duavee Premarin Premphase Prempo	Cenestin Climara Pro Elestrin Enjuvia Estring Estrogel Femring Imvexxy Intrarosa Menest Osphena Prefest
FERTILITY AGENTS (IF COVERED)	cetrorelix ganirelix	Crinone Endometrin Gonal-F Menopur Novarel Ovidrel	Chorionic gonadotropin Follistim AQ Pregnyl
ELECTROLYTE REGULATION		Lokelma	Veltassa

MedImpact.com

Copyright © 2025 MedImpact Healthcare Systems, Inc. All rights reserved. These materials are intended strictly for referential use by MedImpact's business partners. Any other use, or use by any other party, is strictly forbidden and requires written consent of MedImpact Healthcare Systems, Inc.





Portfolio – Preferred Drug List (PDL)

July 1, 2025

PDL DRUG CATEGORY	GENERIC	PREFERRED BRAND	NON-PREFERRED BRAND
OSTEOPOROSIS AGENTS	alendronate calcitonin, synthetic ibandronate raloxifene risedronate risedronate DR teriparatide	Tymlos	Binosto
WEIGHT REDUCTION (IF COVERED)	phentermine phendimetrazine diethylpropion orlistat topiramate	Saxenda Wegovy Zepbound	Belviq Belviq XR Contrave Plenity Qsymia
GASTROINTESTINAL			
IRRITABLE BOWEL & CONSTIPATION	lubiprostone prucalopride	Linzess Movantik Trulance Symproic	Ibsrela Motegrity Zelnorm
INFLAMMATORY BOWEL DISEASE AGENTS	balsalazide disodium mesalamine 1.2G mesalamine DR mesalamine ER sulfasalazine	Pentasa 250mg	Dipentum
PANCREATIC ENZYMES		Creon Zenpep	Pancreaze Pertzye
GENITOURINARY			
DRUGS TO TREAT IMPOTENCY	sildenafil tadalafil vardenafil		Stendra
INFLAMMATORY DISEASE			
AUTOIMMUNE AGENTS	methotrexate	Otrexup	Rasuvo Xatmep
PAIN MANAGEMENT			
HEADACHE/MIGRAINE TREATMENT	almotriptan eletriptan froatriptan naratriptan rizatriptan sumatriptan zolmitriptan	Aimovig Ajovy Emgality Nurtec ODT Qulipta Reyvow Ubrelvy	Onzetra Xsail Tosymra Trudhesa Zavzpret Zembrace Symtouch Zomig Nasal
RESPIRATORY			
BETA-AGONISTS, SHORT- ACTING (SABA)	albuterol HFA levalbuterol tartrate HFA		Proair DigiHaler Proair RespiClick
INHALED CORTICOSTEROIDS (ICS)	Fluticasone Propionate	Arnuity Ellipta	Aerospan Alvesco Armonair RespiClick Armonair DigiClick Asmanex Pulmicort Qvar RediHaler
INHALED CORTICOSTEROID/LONG- ACTING BETA AGONIST (ICS/LABA) COMBINATIONS	Fluticasone/Salmeterol (Advair Diskus) Budesonide/Formoterol (Symbicort)	Advair HFA Breo Ellipta	Airduo (brand and authorized generic) Airduo RespiClick Airduo DigiClickDulera

MedImpact.com



Copyright © 2025 MedImpact Healthcare Systems, Inc. All rights reserved. These materials are intended strictly for referential use by MedImpact's business partners. Any other use, or use by any other party, is strictly forbidden and requires written consent of MedImpact Healthcare Systems, Inc.



Portfolio – Preferred Drug List (PDL)

July 1, 2025

PDL DRUG CATEGORY	GENERIC	PREFERRED BRAND	NON-PREFERRED BRAND
INHALED LONG-ACTING BETA AGONIST (LABA)		Perforomist Serevent Diskus Striverdi Respimat	Arcapta Brovana Foradil
INHALED LONG-ACTING MUSCARINIC ANTAGONISTS (LAMA)	Spiriva Handihaler	Spiriva Respimat	Incruse Ellipta Lonhala Magnair Seebri Neohaler Tudorza Pressair Yupelri
INHALED LONG-ACTING MUSCARINIC ANTAGONISTS AND LONG-ACTING BETA AGONIST (LAMA/LABA) COMBINATIONS	umeclidinium-vilanterol	Anoro Ellipta Stiolto Respimat	Duaklir Pressair Utibron Neohaler Bevespi Aerosphere
INHALED CORTICOSTEROID, LONG-ACTING MUSCARINIC ANTAGONIST, AND LONG-ACTING BETA AGONIST (ICS/LAMA/LABA) COMBINATIONS		Trelegy Ellipta Breztri Aerosphere	
ANTI-LEUKOTRIENES	montelukast zafirlukast		Zyflo Zyflo CR
SPECIALTY			
ANEMIA AGENTS		Retacrit	Aranesp Epogen Mircera Procrit
ASTHMA BIOLOGICS		Dupixent Fasenra Nucala Tezspire Xolair	Cinqair
AUTOIMMUNE AGENTS	infliximab	Adalimumab-ADAZ Ebglyss Enbrel Humira Omnivoh Otezla Rinvoq Selarsdi Simlandi Skyrizi Sotyktu Stelara Taltz Tremfya Xeljanz Xeljanz XR Yesintek	Abrilada Actemra Adalimumab-ryvk Amjevita Bimzelx Cosentyx Cimzia Cyltezo Hadlima Hulio Hyrimoz Idacio Ilumya Inflectra Kevzara Kineret Olumiant Orencia Otulfi Pyzchiva Renflexis Siliq Simponi 50mg Simponi 100mg Simponi Aria

MedImpact.com

Copyright © 2025 MedImpact Healthcare Systems, Inc. All rights reserved. These materials are intended strictly for referential use by MedImpact's business partners. Any other use, or use by any other party, is strictly forbidden and requires written consent of MedImpact Healthcare Systems, Inc.





Portfolio – Preferred Drug List (PDL)

July 1, 2025

PDL DRUG CATEGORY	GENERIC	PREFERRED BRAND	NON-PREFERRED BRAND
			Steqeyma Tyenne Velsipity Wezlana Yuflyma Yusimry Zymfentra
GROWTH HORMONES		Norditropin Genotropin Skytrofa Sogroya	Humatrope Ngenla Nutropin AQ NuSpin Omnitrope Saizen Serostim Zomacton Zorbtive
HEMATOLOGICAL DISORDERS- LEUKOCYTE (WBC) STIMULANTS		Nivistym Ziextenzo	Fulphila Flynetra Granix Leukine Neulasta Neulasta Onpro Neupogen Nyvepria Releuko Rolvedon Stimufend Udenyca Udenyca Onbody Zarxio
HEPATITIS C AGENTS		Epclusa Harvoni Vosevi	Mavyret Sovaldi Zepatier
MULTIPLE SCLEROSIS AGENTS	Glatopa Glatiramer dalfampridine dimethyl fumarate fingolimod 0.5mg teriflunomide	Avonex Betaseron Copaxone 40mg/mL Kesimpta Pen Mavenclad Mayzent Plegridy Rebif Rebif Rebidose Vumerity	Bafiertam Copaxone 20mg/mL Extavia Gilenya 0.25mg Ponvory Tascenso ODT Tecfidera Zeposia
ONCOLOGY AGENTS – HORMONE RECEPTOR- POSITIVE BREAST CANCER		Kisqali Kisqali/Femara Co-pack Verzenio	Ibrance